The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...

16, 2025 – The FDA has approved the drug Omvoh for treating adults with moderately to severely active Crohn's ... bowel disease, after its October 2023 approval as a first-in-class treatment ...

Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...

The median weighted Pediatric Crohn's Disease Activity Index (wPCDAI ... Source Reference: Atia O, et al "Maintenance treatment with vedolizumab in paediatric inflammatory bowel disease (VEDOKIDS ...

After dosing, patients received a maintenance dose of 300 mg by subcutaneous ... "With Omvoh approved in both Crohn's disease and ulcerative colitis, more patients now have a treatment option that may ...

Omvoh is the first biologic treatment in more than 15 years to have disclosed two-year Phase 3 efficacy data in Crohn's disease at the time of approval. 2 "The burden of Crohn's disease on ...

The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.

The Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn disease in adults.

Omvoh is the first biologic treatment in more than 15 years to have disclosed two-year Phase 3 efficacy data in Crohn’s disease at the time of approval. The approval is based on results from the Phase ...

maintenance regimen of Leqembi ® (lecanemab-irmb) for early Alzheimer disease. Lecanemab is a humanized immunoglobulin gamma 1 monoclonal antibody directed against aggregated soluble and ...

Mirikizumab-treated patients achieved statistically significant clinical remission and endoscopic response compared with placebo at week 52. The Food and Drug Administration (FDA) has approved ...